Managers / Q2 2022 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Reported Value
$250M
Q2 2022
Positions
127
Filings on Record
25
2019–present window
Filed
Aug 15, 2022
original filing
Summary
Altium Capital Management LLC reported $250M in U.S.-listed holdings across 127 positions for Q2 2022.
Its largest position, Chinook Therapeutics, represents 4.3% of the portfolio.
Compared with Q1 2022, the fund opened 30 new positions and exited 22.
Portfolio Metrics
Turnover
+31.0%
vs prior filed quarter
Top-10 Concentration
+27.4%
share of reported value
Largest Position
+4.3%
Chinook Therapeutics
New / Exited
30 / 22
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 74.7% · $187M
- Other · 24.3% · $61M
- Equity WRT · 0.6% · $1M
- ADR · 0.5% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| GHGUARDANT HEALTH INC | NEW | +205.0K | 205.0K | +$8M | $8M |
| PEPPERLIME HEALTH ACQUSTN CO | NEW | +735.0K | 735.0K | +$7M | $7M |
| STAASTAAR SURGICAL CO | NEW | +75.0K | 75.0K | +$5M | $5M |
| QDELQUIDELORTHO CORP | NEW | +50.0K | 50.0K | +$5M | $5M |
| CHEMOCENTRYX INC | NEW | +160.0K | 160.0K | +$4M | $4M |
| AMLXAMYLYX PHARMACEUTICALS INC | NEW | +200.0K | 200.0K | +$4M | $4M |
| AKOYA BIOSCIENCES INC | NEW | +296.0K | 296.0K | +$4M | $4M |
| INGNINOGEN INC | NEW | +156.0K | 156.0K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
105 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CHINOOK THERAPEUTICS INC | COM | 4.30% | $11M | 615.0K |
| 2 | BLUBELLUS HEALTH INC NEWhistory → | COM NEW | 3.37% | $8M | 912.0K |
| 3 | ADMAADMA BIOLOGICS INChistory → | COM | 3.17% | $8M | 4.00M |
| 4 | ESPRESPERION THERAPEUTICS INC NEhistory → | COM | 2.96% | $7M | 1.16M |
| 5 | PEPPERLIME HEALTH ACQUSTN CO | CLASS A ORD SHS · *W EXP 10/01/202 | 2.93% | $7M | 1.10M |
| 6 | LNTHLANTHEUS HLDGS INChistory → | COM | 2.33% | $6M | 88.0K |
| 7 | STAASTAAR SURGICAL COhistory → | COM PAR $0.01 | 2.13% | $5M | 75.0K |
| 8 | INSMINSMED INChistory → | COM PAR $.01 | 2.11% | $5M | 268.0K |
| 9 | GKOSGLAUKOS CORPhistory → | COM | 2.07% | $5M | 114.0K |
| 10 | CYMABAY THERAPEUTICS INC | COM | 2.07% | $5M | 1.75M |
| 11 | NOCTURNE ACQUISITION CORP | ORDINARY SHARES · RIGHT 12/26/2025 | 2.05% | $5M | 1.00M |
| 12 | QDELQUIDELORTHO CORPhistory → | COM | 1.94% | $5M | 50.0K |
| 13 | INSPINSPIRE MED SYS INChistory → | COM | 1.75% | $4M | 24.0K |
| 14 | INTRA-CELLULAR THERAPIES INC | COM | 1.71% | $4M | 75.0K |
| 15 | GHGUARDANT HEALTH INChistory → | COM | 1.70% | $4M | 105.0K |
| 16 | MYGNMYRIAD GENETICS INChistory → | COM | 1.61% | $4M | 221.0K |
| 17 | EUCRATES BIOMEDICAL ACQU COR | SHS · *W EXP 10/23/202 | 1.59% | $4M | 533.3K |
| 18 | CHEMOCENTRYX INC | COM | 1.59% | $4M | 160.0K |
| 19 | NEVRO CORP | COM | 1.56% | $4M | 89.0K |
| 20 | AKOYA BIOSCIENCES INC | COM | 1.52% | $4M | 296.0K |
| 21 | INGNINOGEN INChistory → | COM | 1.51% | $4M | 156.0K |
| 22 | TRVITREVI THERAPEUTICS INChistory → | COM | 1.44% | $4M | 1.28M |
| 23 | VERASTEM INC | COM | 1.39% | $3M | 3.00M |
| 24 | DXCMDEXCOM INChistory → | COM | 1.31% | $3M | 44.0K |
| 25 | XTNTXTANT MED HLDGS INChistory → | COM NEW | 1.30% | $3M | 6.25M |
| 26 | CARA THERAPEUTICS INC | COM | 1.29% | $3M | 353.2K |
| 27 | PRCTPROCEPT BIOROBOTICS CORPhistory → | COM | 1.28% | $3M | 98.0K |
| 28 | KARYOPHARM THERAPEUTICS INC | COM | 1.26% | $3M | 700.0K |
| 29 | LIVNLIVANOVA PLChistory → | SHS | 1.25% | $3M | 50.0K |
| 30 | OCULOCULAR THERAPEUTIX INChistory → | COM | 1.12% | $3M | 695.0K |
| 31 | EIGER BIOPHARMACEUTICALS INC | COM | 1.11% | $3M | 440.0K |
| 32 | GLOBAL BLOOD THERAPEUTICS IN | COM | 1.09% | $3M | 85.0K |
| 33 | KURAKURA ONCOLOGY INChistory → | COM | 1.08% | $3M | 147.0K |
| 34 | MASS908 DEVICES INChistory → | COM | 1.03% | $3M | 125.0K |
| 35 | TURMERIC ACQUISITION CORP | CL A · *W EXP 10/08/202 | 1.01% | $3M | 338.7K |
| 36 | KRMDREPRO MED SYS INChistory → | COM | 1.01% | $3M | 995.5K |
| 37 | HRMYHARMONY BIOSCIENCES HLDGS IN | COM | 0.98% | $2M | 50.0K |
| 38 | KROSKEROS THERAPEUTICS INC | COM | 0.97% | $2M | 88.0K |
| 39 | SHOCKWAVE MED INC | COM | 0.92% | $2M | 12.0K |
| 40 | IVERIC BIO INC | COM | 0.91% | $2M | 236.0K |
| 41 | SARISSA CAPITAL ACQUISITN CO | CL A · *W EXP 10/23/202 | 0.89% | $2M | 300.0K |
| 42 | ADICET BIO INC | COM | 0.88% | $2M | 150.0K |
| 43 | AVIDITY BIOSCIENCES INC | COM | 0.87% | $2M | 150.0K |
| 44 | GOSSGOSSAMER BIO INC | COM | 0.87% | $2M | 260.0K |
| 45 | NBIXNEUROCRINE BIOSCIENCES INC | COM | 0.86% | $2M | 22.0K |
| 46 | COLLCOLLEGIUM PHARMACEUTICAL INC | COM | 0.82% | $2M | 116.0K |
| 47 | LAKESHORE ACQUISITION I CORP | ORDINARY SHARES · *W EXP 07/15/202 | 0.81% | $2M | 350.0K |
| 48 | GIGINTERNATIONAL1 INC | COM · *W EXP 04/19/202 | 0.81% | $2M | 250.0K |
| 49 | CHAVANT CAPITAL ACQUISITN CO | ORDINARY SHARES · *W EXP 99/99/999 | 0.80% | $2M | 350.0K |
| 50 | TG VENTURE ACQUISITION CORP | UNIT 08/15/2028 | 0.80% | $2M | 200.0K |
| 51 | JIYA ACQUISITION CORP | COM CL A | 0.79% | $2M | 200.0K |
| 52 | HLMNHILLMAN SOLUTIONS CORP | COM | 0.76% | $2M | 221.0K |
| 53 | ILMNILLUMINA INC | COM | 0.74% | $2M | 10.0K |
| 54 | EYPTEYEPOINT PHARMACEUTICALS INC | COM NEW | 0.71% | $2M | 224.5K |
| 55 | KARUNA THERAPEUTICS INC | COM | 0.66% | $2M | 13.0K |
| 56 | AGIOAGIOS PHARMACEUTICALS INC | COM | 0.65% | $2M | 73.0K |
| 57 | 1847 GOEDEKER INC | *W EXP 06/02/202 | 0.64% | $2M | 6.10M |
| 58 | OMGBPOUTSET MED INC | COM | 0.62% | $2M | 103.9K |
| 59 | DIGITAL HEALTH ACQUISITION C | UNIT 11/02/2026 | 0.61% | $2M | 150.0K |
| 60 | AULT DISRUPTIVE TECHS CORP | COM · *W EXP 99/99/999 | 0.60% | $2M | 262.5K |
| 61 | RZLTREZOLUTE INC | COM NEW | 0.53% | $1M | 411.0K |
| 62 | MORPHIC HLDG INC | COM | 0.52% | $1M | 60.0K |
| 63 | TAILWIND ACQUISITION CORP | COM CL A | 0.51% | $1M | 128.4K |
| 64 | IMMUNOGEN INC | COM | 0.50% | $1M | 280.0K |
| 65 | ALTALTIMMUNE INC | COM NEW | 0.46% | $1M | 98.7K |
| 66 | PROMETHEUS BIOSCIENCES INC | COM | 0.44% | $1M | 39.0K |
| 67 | 2SEVENTY BIO INC | COMMON STOCK | 0.44% | $1M | 83.0K |
| 68 | RELATIVITY ACQUISITION CORP | UNIT 02/10/2027 | 0.41% | $1M | 100.0K |
| 69 | MURPHY CANYON ACQUISITION CO | UNIT 01/25/2027 | 0.40% | $1M | 100.0K |
| 70 | INDUSTRIAL HUMAN CAPITAL INC | COM · *W EXP 11/27/202 | 0.40% | $1M | 200.0K |
| 71 | WESTERN ACQSTN VENTURES CORP | UNIT 09/01/2026 | 0.40% | $1M | 100.0K |
| 72 | OPY ACQUISITION CORP I | COM CL A · *W EXP 09/22/202 | 0.40% | $993,000 | 150.0K |
| 73 | BCLS ACQUISITION CORP | COM CL A | 0.40% | $990,000 | 100.0K |
| 74 | OMEGA ALPHA SPAC | CL A | 0.39% | $985,000 | 100.0K |
| 75 | ARYA SCIENCES ACQU CORP IV | CL A | 0.39% | $981,000 | 100.0K |
| 76 | FAT BRANDS INC | *W EXP 07/16/202 | 0.39% | $965,000 | 227.0K |
| 77 | HLLYHOLLEY INC | COM | 0.34% | $840,000 | 80.0K |
| 78 | RENOVACOR INC | COM · *W EXP 99/99/999 | 0.34% | $839,000 | 1.12M |
| 79 | COLISEUM ACQUISITION CORP | CLASS A ORD SHS · *W EXP 08/22/202 | 0.33% | $830,000 | 113.3K |
| 80 | PEPGPEPGEN INC | COM | 0.32% | $794,000 | 80.0K |
| 81 | ANGOANGIODYNAMICS INC | COM | 0.31% | $767,000 | 39.6K |
| 82 | MUSCLE MAKER INC | COM | 0.28% | $692,000 | 1.80M |
| 83 | LIANYLIANBIO | SPONSORED ADS | 0.27% | $681,000 | 315.2K |
| 84 | STOKSTOKE THERAPEUTICS INC | COM | 0.25% | $634,000 | 48.0K |
| 85 | DDIDOUBLEDOWN INTERACTIVE CO LT | ADS | 0.24% | $588,000 | 60.9K |
| 86 | GERNGERON CORP | COM | 0.23% | $576,000 | 371.4K |
| 87 | ALKSALKERMES PLC | SHS | 0.21% | $536,000 | 18.0K |
| 88 | RLMDRELMADA THERAPEUTICS INC | COM | 0.21% | $532,000 | 28.0K |
| 89 | GSR II METEORA ACQUISITN COR | UNIT 02/24/2027 | 0.20% | $499,000 | 50.0K |
| 90 | COLOMBIER ACQUISITION CORP | CL A · *W EXP 99/99/999 | 0.20% | $490,000 | 66.7K |
| 91 | SAGE THERAPEUTICS INC | COM | 0.19% | $485,000 | 15.0K |
| 92 | HARBOR CUSTOM DEVELOPMENT IN | *W EXP 10/04/202 · *W EXP 05/09/202 | 0.14% | $360,000 | 1.25M |
| 93 | SURGEPAYS INC | *W EXP 10/22/202 | 0.12% | $300,000 | 250.0K |
| 94 | LIGHTNING EMOTORS INC | *W EXP 05/18/202 | 0.10% | $255,000 | 652.2K |
| 95 | TCBWFTC BIOPHARM HOLDINGS PLC | *W EXP 02/08/202 | 0.09% | $223,000 | 941.2K |
| 96 | IMMATICS N.V | *W EXP 07/01/202 | 0.08% | $199,000 | 97.5K |
| 97 | DIGITAL BRANDS GROUP INC | COM | 0.08% | $195,000 | 1.00M |
| 98 | HEALTH SCIENCES ACQ CORP 2 | ORD SHS | 0.04% | $100,000 | 10.0K |
| 99 | CINGWCINGULATE INC | *W EXP 12/10/202 | 0.03% | $85,000 | 270.0K |
| 100 | DIRECT DIGITAL HOLDINGS INC | *W EXP 02/15/202 | 0.03% | $70,000 | 180.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $266M | 98 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.